相关实验视频

Updated: Jul 11, 2025

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

Published on: February 27, 2019

高瘤负担对化学抗原受体T细胞免疫疗法的影响:一篇评论

Marco Ventin¹, Giulia Cattaneo¹, Luke Maggs¹

¹Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston.

|November 9, 2023

概括

化学抗原受体 (CAR) T细胞疗法显示出希望,但面临着高瘤负担和固体瘤的挑战. 了解这些局限性是提高癌症患者CAR-T细胞疗效和安全性的关键.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
细胞疗法细胞疗法

背景情况:

化学抗原受体 (CAR) T细胞疗法已经改变了血液癌症治疗.
然而,没有反应,复发和不良事件限制了它的有效性.
在固体瘤中,CAR T细胞疗法表现出有限的成功.

研究的目的:

审查瘤负担对CAR T细胞疗法的有效性和安全性的影响.
讨论高瘤负担,炎症和免疫失调所带来的挑战.
探索新兴的战略,以克服这些障碍在固体瘤.

主要方法:

对临床前和临床数据的文献综述.
分析瘤微环境与CAR T细胞功能之间的相互作用.
讨论当前和未来的临床方法.

主要成果:

高瘤负担和瘤微环境显著损害CAR T细胞的功能和持久性.
系统性炎症和免疫失调导致治疗失败.
目前正在制定战略,以加强对固体瘤的CAR T细胞治疗.

结论:

了解CAR T细胞治疗在高瘤负担环境中的局限性至关重要.
克服与瘤微环境相关的挑战对于更广泛的应用至关重要.
需要新的方法来提高CAR T细胞在固体恶性瘤中的疗效.

更多相关视频

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Droplet-based Cytotoxicity Assay to Assess Chimeric Antigen Receptor T cells at the Single-cell Level

Droplet-based Cytotoxicity Assay to Assess Chimeric Antigen Receptor T cells at the Single-cell Level

Published on: March 14, 2025

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.